Does RANIBIZUMAB Cause Choroidal neovascularisation? 195 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 195 reports of Choroidal neovascularisation have been filed in association with RANIBIZUMAB (CIMERLI). This represents 1.3% of all adverse event reports for RANIBIZUMAB.
195
Reports of Choroidal neovascularisation with RANIBIZUMAB
1.3%
of all RANIBIZUMAB reports
1
Deaths
10
Hospitalizations
How Dangerous Is Choroidal neovascularisation From RANIBIZUMAB?
Of the 195 reports, 1 (0.5%) resulted in death, 10 (5.1%) required hospitalization.
Is Choroidal neovascularisation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RANIBIZUMAB. However, 195 reports have been filed with the FAERS database.
What Other Side Effects Does RANIBIZUMAB Cause?
Death (2,250)
Off label use (1,467)
Visual acuity reduced (1,342)
Visual impairment (1,185)
No adverse event (1,012)
Drug ineffective (831)
Blindness (760)
Vision blurred (711)
Eye pain (632)
Cerebrovascular accident (543)
What Other Drugs Cause Choroidal neovascularisation?
PEGCETACOPLAN (52)
AFLIBERCEPT (47)
VERTEPORFIN (47)
BEVACIZUMAB (38)
BROLUCIZUMAB-DBLL (38)
PENTOSAN POLYSULFATE (17)
PREDNISONE (10)
SILDENAFIL (10)
LUCENTIS (9)
AVACINCAPTAD PEGOL (7)
Which RANIBIZUMAB Alternatives Have Lower Choroidal neovascularisation Risk?
RANIBIZUMAB vs RANIMUSTINE
RANIBIZUMAB vs RANITIDINE
RANIBIZUMAB vs RANITIDINE\RANITIDINE
RANIBIZUMAB vs RANOLAZINE
RANIBIZUMAB vs RAPAMUNE